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In the past few years, inﬂammation has emerged as a major driving force of atherosclerotic lesion devel-
opment. It is now well-established that from early lesion to vulnerable plaque formation, numerous cel-
lular and molecular inﬂammatory components participate in the disease process. The most prominent
cells that invade in evolving lesions are monocyte-derived macrophages and T-lymphocytes. Both cell
types produce a wide array of soluble inﬂammatory mediators (cytokines, chemokines) which are criti-
cally important in the initiation and perpetuation of the disease. This review summarizes the currently
available information from mouse studies on the contribution of a speciﬁed group of cytokines expressed
in atherosclerotic lesions, viz. interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, IL-20) and
macrophage-associated cytokines [tumour necrosis factor-a (TNF-a); macrophage migration inhibitory
factor (MIF); interferon-g (IFN-g); colony stimulating factors G-CSF,-M-CSF,-GM-CSF) to atherogenesis.
Emphasis is put on the consistency of the effects of these cytokines, i.e. inasmuch an effect depends
on the experimental approach applied (overexpression/deletion, strain, gender, dietary conditions,
and disease stage). An important outcome of this survey is (i) that only for a few cytokines there is
sufﬁcient consistent data allowing classifying them as typically proatherogenic (IL-1, IL-12, IL-18, MIF,
IFN-g, TNF-a, and M-CSF) or antiatherogenic (IL-10) and (ii) that some cytokines (IL-4, IL-6 and
GM-CSF) can exert pro- or anti-atherogenic effects depending on the experimental conditions. This
knowledge can be used for improved early detection, prevention and treatment of atherosclerosis.
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1. Introduction
It is now well-accepted that atherosclerosis is not only
merely a lipid disorder, but also a chronic inﬂammatory
disease.
1 Inﬂammation is recognized as a major contributor
to atherogenesis through adverse effects on lipoprotein
metabolism and arterial wall biology, and both the innate
(monocyte-derived macrophages) and the acquired
immune system (T-cells) have been implicated in the
atherogenic process.
1,2 Monocytes and T-cells migrate from
the circulation into the intima of the arterial wall where
they differentiate into macrophages, which then take up
modiﬁed lipoproteins thereby transforming into foam cells.
Monocyte-derived macrophages are abundantly present at
all stages of the disease process.
1,3 Their pivotal role in
atherogenesis has been demonstrated by the attenuation of
lesion formation in monocyte-deﬁciency in both ApoE
2/2
mice and LDLR
2/2 mice.
4,5
In addition to cells of the monocyte/macrophage lineage,
CD4þ and CD8þ T-cells are present in atherosclerotic
lesions. Macrophages and T-lymphocytes together produce
a wide array of cytokines that can exert both pro- and anti-
inﬂammatory effects (Figure 1). Pro-inﬂammatory cytokines
of the interleukin category are considered to be key players
in the chronic vascular inﬂammation that is typical for
atherosclerosis.
3 Presence of interleukins and their recep-
tors has been demonstrated in atheromatous tissue, and
the serum levels of several of these cytokines have been
found to correlate positively with (coronary) arterial
disease and its sequelae. Besides interleukins, macrophage-
associated cytokines such as tumour necrosis factor
(TNF)-a, macrophage migration inhibitory factor (MIF),
interferon (IFN)-g and colony stimulating factors (CSFs)
have emerged as key factors in the pathogenesis of
atherosclerosis.
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the cytokines expressed in atherosclerotic plaques revealed
that there is a balance between pro-inﬂammatory and anti-
inﬂammatory cytokines and that this balance is crucial for
lesion development (Figure 2A). For example, the secreted
cytokines of type 1 CD4þ T-helper cells (TH1 cells) such as
interleukin-2 (IL-2), IL-12, IFN-g, TNF-a and TNF-b are
pro-inﬂammatory and exacerbate atherosclerotic disease,
whereas TH2 cytokines such as IL-4, IL-5, IL-10, and IL-13
are considered to be mainly atheroprotective and can
counteract TH1 cytokine activity/production.
7–9 Notably,
this attractive black-and-white concept of TH1 and TH2
responses controlling the development of atherosclerosis
may not be true at all stages of plaque development.
10
Important insight into the role of cytokines in atherogenesis
has been gained from animal studies, in particular mouse
studies. Mouse atherosclerosis models resemble humans in
that the most prominent cells involved in lesion development
are monocyte-derived macrophages and T-lymphocytes. It
is important to note, however, that all standard mouse
atherosclerosis models (e.g. ApoE
2/2 mice, LDLR
2/2 mice,
and ApoE*3Leiden-mice)
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Figure 1 Cytokines involved in atherogenesis and their cellular source and targets. (1) LDL particles penetrate the endothelial cell layer and are oxidized in the
intima (oxLDL). Pro-inﬂammatory lipids are released from oxLDL and induce expression of cytokines in EC (e.g. IL-1, MIF, M-CSF, and GM-CSF) and SMCs (M-CSF).
MIF and M-CSF can function as a chemotactic factor for monocytes and T-cells. GM-CSF is a major regulator of dendritic cell differentiation and involved in
lesional dendritic cell accumulation. (3) TNF-a and MIF are involved in the autocrine activation of macrophages thereby amplifying inﬂammation. IL-12 and
IL-18 formed by macrophages and IL-4 (e.g. from NKT) promote the differentiation of native T-cells into TH1-cells and TH2-cells, respectively. IL-12 and IL-18
are potent inducers of IFN-g. (4) TH1-cells can further activate macrophages (inﬂammatory cascade) whereas TH2-cells produce anti-inﬂammatory mediators
(e.g. IL-4, IL-10, and IL-13) with opposite effect on macrophages, T-cells and EC. IL-4 (TH2-associated) impair the development of TH1-cells from pre-TH-cells
(not shown). Vice versa, IFN-g inhibits TH2-cell development. Also, TH2-derived IL-4 and IL-13 are potent stimulators of antibody production (on B-cells, not
shown), IL-5 is involved in B-cell differentiation and eosinophilic inﬂammation. (5) Macrophages are further stimulated by T-cell derived IFN-g as well as IL-1
and TNF-a (also from other sources) together resulting in an ampliﬁcation of the inﬂammatory response. (6) SMCs are targets for many of the macrophage-
and T-cell-derived cytokines and participate in this self-perpetuating inﬂammatory cycle by producing and secreting a range of pro-inﬂammatory factors
among which are IL-1, TNF-a, and IFN-g.
Cytokines and atherosclerosis: studies in mice 361which is prone to TH1-type immune responses and inherently
underestimates the impact of TH2-type responses.
The TH1 cytokines IL-1b and TNF-a are among the most
important cytokine mediators of the inﬂammatory response,
12
and concordantly a large number of studies have attempted
to delineate the role of these cytokines in atherogenesis.
However, the role of other members of the interleukin
family in atherogenesis is increasingly appreciated. Here,
we summarize all currently available information from
mouse atherosclerosis studies investigating the role of
the interleukins IL-1,-2,-4,-5,-6,-10,-12,-18, and -20, the
macrophage-associated cytokines TNF-a, MIF , IFN-g,a n d
the colony stimulating factors G-CSF, M-CSF, and GM-CSF.
Particular attention is paid to the experimental conditions
employed (cf, strain, gender, type of diet, disease stage,
and mode of intervention; experimental details are provided
in Table 1) as different or even contradictory study outcomes
may be related to differences in experimental set-up.
2. Interleukin-1
IL-1 is a prototypic pro-inﬂammatory cytokine that exists in
two forms, IL-1a and IL-1b, both of which exert similar but
not completely overlapping biological functions mediated
through the IL-1 receptor (IL-1R). After binding to IL-1R,
IL-1 induces the production of a broad spectrum of cytokines
and chemokines as well as the expression of adhesion
molecules on endothelial cells (EC), thus leading to the
recruitment of inﬂammatory cells. In addition, IL-1 contri-
butes to the development of vascular damage by stimulating
cell proliferation and differentiation and the release of
matrix-degrading enzymes. The IL-1R antagonist (IL-1Ra) is
a structural homologue of IL-1 that binds to IL-1R but does
not induce any cellular responses and is therefore a
natural inhibitor of IL-1-activity.
13
The role of IL-1 in atherogenesis has been investigated
through inﬂuencing its level or activity (Table 1). Elhage
et al.
14 showed that short-term perfusion with a recombi-
nant IL-1Ra preparation reduces fatty-streak formation in
male and female ApoE
2/2-mice fed a cholesterol/
cholate-rich diet, without evident interference with lipid
metabolism. This study lacked, however, proper controls
(e.g. no sham minipump). Merhi-Soussi et al.
15 demon-
strated that atherosclerosis development is inhibited in
ApoE
2/2-mice overexpressing either secreted IL-1Ra or
intracellular IL-1Ra and fed a cholesterol-rich diet, thus pro-
viding more solid proof to the observations by Elhage.
Devlin et al.
16 used two strains of mice, either with
deﬁcient or excess IL-1Ra. IL-1Ra
2/2/C57/BL6/J-mice fed
a cholesterol/cholate-diet had a 3-fold decrease in
non-HDL-cholesterol and a trend toward increased foam-cell
lesion area compared to wild-type littermate controls.
LDLR
2/2-mice expressing high levels of murine IL-1Ra and
fed a cholesterol-saturated fat diet showed a 40% increase
in non-HDL-cholesterol, consistent with the IL-1Ra
2/2
data, but there was no signiﬁcant change in lesion size.
However, when IL-1Ra-overexpressing LDLR
2/2-mice were
fed a high-cholesterol(HC)/high-fat (HF) diet containing
cholate, lesion area was 40% lower than in non-transgenic
controls; no signiﬁcant differences in plasma cholesterol or
lipoproteins between the experimental groups were
observed under these conditions.
Studies by Isoda et al.
17,18 further clariﬁed the role of
IL-1Ra in atherosclerotic lesion development. The studies
focused on the comparison of atherosclerotic lesion
between IL-1Ra
þ/þ/ApoE
2/2 and IL-1Ra
þ/2/ApoE
2/2-mice,
because IL-1Ra
2/2/ApoE
2/2-mice were signiﬁcantly leaner,
had signiﬁcantly elevated total plasma cholesterol,
decreased HDL-cholesterol levels, and severe fatty livers
when compared with the other mice. The lowering of serum
levels of IL-1Ra in IL-Ra
þ/2/ApoE
2/2-mice to approximately
half of those in IL-1Ra
þ/þ/ApoE
2/2 was associated with a
signiﬁcant increase in lesion development during early
atherogenesis. At later stages, the differences of lesion size
between these mice disappeared, but, most importantly,
(lack of) IL-1Ra appeared to have modulated plaque compo-
sition during lesion progression, with a signiﬁcant increase
in macrophages and depletion of smooth muscle cells (SMC)
in IL-1Ra
þ/2/ApoE
2/2, suggesting reduced plaque stability.
Merhi-Soussi et al.
15 also noticed massive vascular inﬂam-
mation in IL-1Ra
2/2/ApoE
2/2 mice with marked macrophage
inﬁltration in the adventitia and severe destruction of elastic
lamina, paralleled by severe illness and high death rate.
Taken together, the reported effects of IL-1Ra on early
lesion development and plaque composition point to an
important role of IL-1 signalling in atherogenesis. In line,
IL-1b
2/2/ApoE
2/2 showed a signiﬁcant 30% decrease in
atherosclerosis at 12 and 24 weeks of age compared with
that in IL-1b-expressing ApoE
2/2 mice.
19 There was no sig-
niﬁcant difference in plasma lipid levels between the two
genotypes. Kamari et al.
20 conﬁrmed these observations
using IL-1b
2/2/C57/BL6-mice and additionally demon-
strated that genetic deletion of IL-1a reduced lesion area
by 56%. Of note, IL-1a
2/2 mice displayed high levels of
non-HDL-cholesterol whereas IL-1b
2/2-mice had higher
Figure 2 Categorization of cytokines into pro-atherogenic and anti-
atherogenic cytokines based on their effects in mouse atherosclerosis
models. (A) The balance between pro-inﬂammatory and anti-inﬂammatory
cytokines is crucial for lesion development and imbalance is colloquially
referred to exacerbate atherosclerotic disease. (B) Overview of the cytokines
with consistent anti-atherogenic effects (green circle), pro-atherogenic
effects (red circle), or variable, dual function (intersection).
R. Kleemann et al. 362levels of HDL-cholesterol. Transplantation of IL-1a
2/2 or
IL-1b
2/2 bone marrow (BM) in irradiated C57/BL6-mice
reduced early lesion formation by 59 and 33%, respectively,
when compared with wild-type BM transplanted mice,
without changing plasma lipids.
20
The evidence for an important role of IL-1 signalling in
atherosclerosis is further strengthened by a study by Chi
et al.
21 who showed that the absence of IL-1R markedly
reduces the progression of atherosclerosis in ApoE
þ/2-mice
under experimental conditions known to favour the aggrava-
tion of vascular lesions, i.e. 24 weeks of exposure to HF-diet
and P. gingivalis. The effect of IL-1R absence persisted
whether the inciting factors were genetic, dietary, or infec-
tious, alone or in combination, thus highlighting the promi-
nent role of IL-1 signalling in the atherosclerotic process
and emphasizing its attractiveness as a therapeutic target.
3. Interleukin-2
IL-2 is a pro-inﬂammatory cytokine produced by TH1 lympho-
cytes. Intraperitoneal injection of IL-2 into ApoE
2/2-mice
fed with HF-diet enhances atherosclerosis, while anti-IL-2
antibody treatment has a protective effect, indicating that
IL-2 is atherogenic.
22
4. Interleukin-3
See below under CSFs.
5. Interleukin-4
IL-4, a TH2c y t o k i n ew i t hak e yr o l ei nT H2-cell differentiation,
is produced by activated T-lymphocytes and mast cells, and
can exert both pro- and anti-inﬂammatory effects.
9,23,24
The role of IL-4 in atherosclerosis has been investigated in
several mouse models (Table 1).
23,25–27
Davenport and Tipping
23 found that IL-4
2/2/ApoE
2/2-
mice had a signiﬁcant reduction in plaque area in the aortic
root compared to ApoE
2/2-mice at 30 weeks of age. At 45
weeks, there were no signiﬁcant differences in lesion sizes
in the aortic root between the strains; however, IL-4
2/2/
ApoE
2/2mice showed a marked decrease in atherosclerosis
in their aortic arch compared to ApoE
2/2 mice.
King
25 demonstrated that immune cell-speciﬁc deﬁciency of
IL-4 in hypercholesterolemic, cholate-fed female LDLR
2/2
mice, produced by repopulation with BM stem cells from
IL-4
2/2 mice, led to a reduction in atherosclerosis in the
arch/thoracic regions of the aorta, but not in the aortic
root. The same group reported no effect of genetic
IL-4-depletion in models of cholesterol-induced atherosclerosis
(female LDLR
2/2 mice; after 4 weeks), angiotensin-II-induced
atherosclerosis (male ApoE
2/2 mice; after 4 weeks), and
spontaneous atherogenesis (male and female ApoE
2/2 mice;
up to 36 weeks).
27 I.p. administration of mouse IL-4 protein
during 30 days had also no effect on atherogenesis in
ApoE
2/2 fed a normal chow or a HF-diet.
27 In none of these
experiments modulation of IL-4 altered plasma cholesterol.
Using a model of accelerated fatty streak formation
induced by heat-shock-protein-65 or Mycobacterium
tuberculosis, George et al.
26 found that fatty streak for-
mation in IL-4
2/2 mice was signiﬁcantly reduced compared
with lesions in wild-type C57/BL6 mice, lending support to a
pro-atherogenic character of IL-4.
However, in another study by the same group, fatty streak
formation in the aortic root of C57/BL6 fed a HC-diet was
not inﬂuenced by IL-4 deﬁciency.
24 Notably, the lesions in
this study were not as advanced as in the above studies
using ApoE
2/2.
At odd with these ﬁndings, IL-4 injection decreased aortic
lesion size in mice under conditions of mild hypercholester-
olemia, suggesting that exogenous and endogenous IL-4 may
have opposite effects.
28
Overall, the data show that IL-4 can play a role in the
development of atherosclerosis at various vascular sites.
The net effect of IL-4 may depend on the disease stage,
reﬂecting its dual, i.e. pro- and anti-inﬂammatory, character.
6. Interleukin-5
IL-5 is mainly produced by TH2 cells and mast cells. In
LDLR
2/2 mice which were reconstituted with wild-type or
IL-5
2/2 BM cells, Binder et al.
29 established that IL-5 links
adaptive and natural immunity speciﬁc for epitopes of oxi-
dized low-density lipoprotein (oxLDL) and had an overall
atheroprotective role.
7. Interleukin-6
IL-6 is a multifunctional cytokine that regulates various
aspects of the immune response, acute-phase reaction,
and haematopoiesis. IL-6 is inducible by IL-1, and conse-
quently concentrations in serum are often a reﬂection of
IL-1 activity in vivo. Nonetheless, IL-6 has been identiﬁed
as an independent risk factor for coronary artery disease.
Direct involvement of IL-6 in atherosclerotic lesion develop-
ment was suggested by experiments in which mice had been
treated for 6–21 weeks with recombinant IL-6 (rIL-6).
30 rIL-6
treatment increased lesion size in HF/cholate-fed C57/BL6
and ApoE
2/2 mice 5.1- and 1.9-fold, respectively when
compared to lesions in saline-treated animals (Table 1).
Total cholesterol levels were unchanged between rIL-6-
treated and non-treated groups. Seemingly contrasting
these observations with supra-physiological injections of
rIL-6 is a study reporting that IL-6
2/2 mice developed 1.7
times larger fatty streak lesions than C57/BL6 after 15
weeks on atherogenic Paigen diet.
31
In another study, using chow-fed ApoE
2/2 mice that were
IL-6 mono- or double-deﬁcient, there was a tendency for
decreased fatty streak formation when compared with
ApoE
2/2 mice, despite a signiﬁcant increase in plasma
non-HDL cholesterol in IL-6
2/2/ApoE
2/2.
32 However, when
female IL-6
2/2/ApoE
2/2 mice were maintained for 1 year
on a normal mouse-chow, the animals showed similar
hypercholesterolemia to IL-6
þ/þ/ApoE
2/2 but presented
signiﬁcantly larger and more calciﬁed lesions.
32
In a very similar study, Schieffer et al.
33 used male
IL-6
2/2/ApoE
2/2 double knockout mice on a normal chow
diet for 1 year. A lifetime deﬁciency of IL-6 in the male
ApoE
2/2 model resulted in enhanced atherosclerotic
lesion formation, similarly as reported by Elhage et al.,
32
but signiﬁcantly higher levels of total cholesterol, LDL,
and VLDL, which is deviant from the ﬁndings with female
IL-6
2/2/ApoE
2/2. Schieffer et al. also reported reduced
collagen metabolism and decreased recruitment of
inﬂammatory cells to the atherosclerotic plaque in male
IL-6
2/2/ApoE
2/2 mice.
Cytokines and atherosclerosis: studies in mice 363Table 1 Summary of the reviewed atherosclerosis studies and their experimental conditions, i.e. mouse model, gender, composition of diet, animal age, and treatment period, effect on
cholesterol, atherosclerotic lesion size, and lesion composition
Cytokine Mouse model (treatment) Diet Age at start of
treatment þ treatment
period
Cholesterol Lesion size Composition Reference
IL-1Ra ApoE
2/2 (M/F)þrec hu IL-Ra HFDþcholate 16% fat/1.16% chol/
0.5% cholate
2mþ 1m $ 56%#(M) Fatty streak 14
63%#(F)
s human IL-1Ra Tg/ApoE
2/2
(M)
HFD 1.25% chol 10 w þ 10 w $ 47% #/53% # 15
ic human IL-1Ra Tg/ApoE
2/2
(M)
HFD 1.25% chol 10 w þ 10 w $ 40% #/ 67% # 15
IL-1Ra
2/2/ApoE
2/2 (M) HFD 1.25% chol 10 w þ 7 w 42% # No atherosclerosis;
massive inﬂammation
15
IL-1Ra
2/2/C57Bl/6J HFD 7.5% fat/1.25%
chol/ 0.5%
cholate
4wþ 12 w 3 x # Tendency to increased
foam cell lesion area
16
IL-1RaTg/LDLR
2/2 HC/HF 4 w þ 10 w 40% "$ 16
HC/
HFþcholate
4wþ 4w $ 40% #
IL-1R
2/2/ApoE
þ/2 vs. IL-
1R
þ/2/ApoE
þ/2
HFDþcholate 15% fat/1.25% chol/
0.5% cholate
10 w þ 14/24 w 14 w: $ Milder 21
24 w:14x#
IL-1R
2/2/ApoE
þ/2 vs. IL-
1R
þ/2/ApoE
þ/2
Chow 0.02% chol/ 4.5% fat 10 w þ 14/24 w 14 w: $ Milder 21
24 w: 3x#n.s.
IL-1Ra
þ/2/ApoE
2/2 vs. IL-
1Ra
þ/þ/ApoE
2/2 (vs. IL-
1R
2/2/ApoE
2/2)
Chow 0.02% chol/ 4.5% fat 16 w þ 24 w $ 16 w: 30%" A-SMA# 17,18
24 w: "n.s. MOMA-2"
24 w ""
IL-1a IL-1a
2/2 C57BL/6 HF/HC 17% fat/1.25% chol/
0.5% cholate
6wþ 19 w " (non-HDL) 56% # 20
C57BL/6þIL-1a
2/2 BMT HF/HC 17% fat/1.25% chol/
0.5% cholate
6wþ 16 w $ 59% # 20
IL-1b IL-1b
2/2/ApoE
2/2 (M) Chow 4.6% fat/ ,0.02%
chol
0wþ 12/24 w $ 33%#/32%# 19
IL-1b
2/2 C57BL/6 HF/HC 17% fat/1.25%chol/
0.5% cholate
6wþ 19 w " (HDL) 50% # 20
C57BL/6þIL-1b
2/2 BMT HF/HC 17%fat/1.25% chol/
0.5% cholate
6wþ 16 w $ 33% # 20
IL-2 ApoE
2/2 (M)þrmIL-2 HF 21% fat/ 0.15% chol 6 w ND " More advanced 22
ApoE
2/2 (M)þa-mouse IL-2 # Less advanced
IL-4 IL-4
2/2/ApoE
2/2 (MþF) Chow 6, 15, 30, 45 w $ 30 w:27%# 23
45 w: #
IL-4T KO/C57BL/6J Paigen 17% fat/ 1.25 chol 15 w $$ 24
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4IL-4
2/2/C57BL/6JþHSP65 (F) HF Teklad diet
(TD 90221)
15 w $# 26
LDLR
2/2þIL-4
2/2 BMT HF 21% fat/1.25% chol/
0.5% cholate
4w $ Root: $$ 25
Arch: 69%#
LDLR
2/2/IL-4
2/2(F) HF Teklad
88137 or
Teklad 90221
21% butter fat/
0.15% chol
8–10 w þ 4w $$ 27
21% fat/0.15%chol/
0.5% cholate
ApoE
2/2 /IL-4
2/2(M, F) Chow or HF/HC 21% butter fat/
0.15% chol
8–10 w þ 36 w $$ 27
ApoE
2/2þi.p. IL-4 Normal chow or
HF Teklad
88137
21% butter fat/
0.15% chol
8wþ 30 d $$ 27
C57BL/6JþIL-4 (M) Teklad diet
96354
20% fat/ 1.5% chol/
0.5% cholate
15 w $ 90%# 28
IL-5 LDLR
2/2þIL-5
2/2 BMT Teklad diet
94059
15.8% fat/1.25%
chol
16 w ND Root: " 29
Arch: "
IL-6 C57Bl/6 (M)þrec mouse IL-6 HFDþcholate 20% fat/1.5% chol/
0.5% cholate
3wþ 21 w $ 5.1 x " 30
ApoE
2/2 (M)þrec mouse IL-6 LFD (chow) 5.67% fat/0% chol 3 w þ 21 w $ 2.4 x " 30
ApoE
2/2 (M)þrec mouse IL-6 HFDþcholate 20% fat/1.5% chol/
0.5% cholate
3wþ 6w $ 1.9 x " 30
IL-6
þ/2/ApoE
2/2 (F) LFD (chow) 0 w þ 16 w $ 28%#(n.s.) 32
IL-6
2/2/ApoE
2/2 (F) LFD (chow) 0 w þ 16 w 26%"(sign.) 29%#(n.s.) 32
IL-6
2/2/ApoE
2/2 (F) LFD (chow) 0 w þ 1y $ 1.9 x " Calciﬁcation area: 4.1 x " 32
IL-6
2/2/C57Bl/6 (F) Paigen 15% fat/1.25% chol/
0.5% cholate
8–10 w þ 15 w ND 70%" 31
IL-6
2/2/LDLR
2/2 (M, F) Chow 5 w þ 16 w $$ M—45% (n.s.) 34
F—38% (n.s.)
IL-6
2/2/LDLR
2/2 (M, F) Western-type
diet
20% fat/1.5% chol 5 w þ 16 w $$ M—27% (n.s.) 34
F—19% (n.s.)
IL-6
2/2/LDLR
2/2 (M, F) Paigen diet 15% fat/1.25% chol/
0.5% cholate
5wþ 16 w $$ M—15% (n.s.) 34
F—22% (n.s.)
IL-6
2/2/ApoE
2/2 (M) Chow 0 w þ 53+4 w 60% " 1.4–1.9 x " 33
IL-10 mIL-10TG/C57BL/6J HF 15% fat/1.25% chol/
0.5%cholate
15 w $ 2.5x# 40
IL-10
2/2/C57BL6 HF 15% fat/1.25% chol/
0.5%cholate
15 w HDL# 2x" Fatty streak 40
LDLR
2/2þIL-10Tg BMT HF (TD94059) 15.8% fat/1.25%
chol
20 w $ 2x# 44
IL-10
2/2 /ApoE
2/2 (MþF) Chow 16 w þ 48 w total chol $ 16 w:3x" SMCþinﬂammatory cells
$
95
VLDL#LDL" 48 w: $
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5Table 1 Continued
Cytokine Mouse model (treatment) Diet Age at start of
treatment þ treatment
period
Cholesterol Lesion size Composition Reference
IL-10
2/2/ C57BL/6J (F) HF 18% fat/1.25% chol/
0.5% cholate
8wþ 16 w $ SPF:3x" Macrophages$ 41
CONV:30x" T-cells 2.5x"
Collagen#
LDLR
2/2þIL-10
2/2 BMT HF 15% fat/1.25% chol 14 w $ 35%" SMC$ 45
Collagen 49%#
Macrophage 62%"
T-cells 116%"
ApoE
2/2þmIL-10-HVJ (M) HF/HC 7.5% fat/1.25%
chol/0.5% cholate
9w $ 2.5x# Macrophages 2x# 42
T-cells 2x"
Collagen $
ApoE
2/2þAAV2/5-mIL-10 HF 8 w cholþTG # 31%# MCP-1# 43
LDLR
2/2þAAV2-hIL-10 HC 2%chol 18 w # Macrophages # 39
Nitrotyrosine #
IL-12 IL-12
2/2/ApoE
2/2 (MþF) Chow 6, 15, 30, 45 w $ 30 w:52%# 30 w: fewer macrophages 23
45 w:$
ApoE
2/2þrecmIL-12 (M) Chow 30 d $" More advanced 47
CD3þ cells "
LDLR
2/2þIL-12-PADRE (F) Western-type
diet
15% fat/0.25% chol 2 w diet þ6 w collar $ 68.5%# 4.2x" SM-actin 2.8x"
collagen
48
Macrophages$
IL-18 ApoE
2/2þIL-18 Chow 30 d $ 2.2x" T-cells 4.5x" 49
MHCIIþcells 4.4x"
IFN-g
2/2/ApoE
2/2þIL-18 Chow 30 d $$ $ 77
IL-18
2/2/ApoE
2/2 24 w 50%" 35%# I-A
b gene # 50
CD4þ cells#
SMactin "
ApoE
2/2þpcDNA3-mIL-18BP
(M)
9w $ 24%# Macrophages 50%# 51
T-cells 67%#
2x"SMC
85%" collagen
TUNEL 3.5x#
IL-20 ApoE
2/2þintramuscular
electroporation of IL-20 (F)
Atherogenic
diet
0.15% chol 10 w ND 1.4x" Macrophages $ 54
Mig, I-TAC, TNF-a, IL-6 "
TNFR p55
2/2/ApoE
2/2 Chow 0 w þ 64 w $$ $ 57
p55
2/2 or wt grafts in
ApoE
2/2
Chow 9% fat 6 w þ 8 w post operatively not reported Lumen 31%" SMC proliferation # 58
p55
2/2/ApoE
2/2(F) Chow 9% fat 60 w $ 12%# 58
p55
2/2/C57Bl6(c.pneumoniae
infected)
HF/HC 15% fat/ 1.25% chol/
0.5% cholate
9wþ 12/16 w $$ 59
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6p55
2/2/C57Bl6 (F) HF/HC 15% fat/ 1.25% chol/
0.5% cholate
6–8wþ 14 w $ 2.3x"$ 55
p55
2/2/ p75
2/2/ p55
2/2
p75
2/2/C57BL6
HF/HC 15% fat/ 1.25% chol/
0.5% cholate
6wþ 18 w $ 2.4x"/$/2.4x" 56
TNF-a TNF
2/2/E3Leiden (F) Western-type
diet
15% fat/ 1% chol 8 w þ 20 w $$ Early" necrosis# 64,65
Necrosis "
Apoptosis "
TNFa
2/2/ApoE
2/2 Western-type
diet
21% fat/ 0.15% chol 4 w þ 10/40 w "n.s./ $ 50%#/ 60%# 60
TNFa
2/2/ApoE
2/2(BMT) Western-type
diet
21% fat/ 0.15% chol 10 w þ 25 w $ 83%# 60
TNFa
2/2/ApoE
2/2(murine
sTNF-RI/Fc chimera)
Chow 7 w þ 25 w "n.s. 75%# 60
p55
2/2/ApoE
2/2 Chow 0 w þ 64 w $$ $ 57
p55
2/2 (M) Atherogenic
diet
15% fat/ 1.25% chol/
0.5%cholate
9wþ 12/16 w $$ 59
p55
2/2/ApoE
2/2 (F) Atherogenic
diet
15% fat/ 1.25% chol/
0.5% cholate
6–8wþ 14 w $ Lesion size 2.3x" Cell number# 55
Scavenger receptor
expression"
TNFa
2/2/C57BL/6 (F) HF/HC 15% fat/ 1.25% chol/
0.5% cholate
6wþ 16 w 46%"$ 56
TNFa
2/2/ApoE
2/2 (MþF) Chow 0 w þ 12 w $ 27%# 61
TNF
2/2/C57BL/6 (M) HF/HC 17% fat/ 1.25% chol/
0.5% cholate
8–10 w þ 20 w 61.5%"HDL 17.8x# 65
16.9%#IDL/LDL
21.6%#VLDL
TNF
2/2/ ApoE
2/2 (F) HF/HC 17% cocoa butter,
1.25% cholesterol
6wþ 26 w not reported 30%# Reduced wall-thickness 62
tmTNF/C57Bl6 HF/HC 17% fat/ 1.25% chol/
0.5% cholate
8–10 w þ 20 w $ 1.8x#n.s. 65
Anti-TNF ApoE
2/2þTNFbp (MþF) HF/HC 16% fat/1.15% chol/
0.5% cholate
8wþ 4w $ M $ 14
F: 35%# n.s.
IFN-g IFNg
2/2/ApoE
2/2 (MþF) Chow 36 w $ M: 42%# Neutral lipid,
macrophages, T-cells,
collagen $
75
F: $
HF (TD88137) 0.15% chol/20%
butterfat
8wþ 12 w $ M: 74%# Neutral lipid,
macrophages, T-cells,
collagen $
F: $
ApoE
2/2 (M)þmIFNg IP Chow 16 w þ 4 w 15%#VLDL 2x" 2,7x" T-cells 76
3.3x" MHCII
þ cells
IFN-gR
2/2/ApoE
2/2 (F) Western-type
diet
21% fat/0.15% chol 5 w þ 12 w FC" 59%# lipid
content
Smaller 53
Continued
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7Table 1 Continued
Cytokine Mouse model (treatment) Diet Age at start of
treatment þ treatment
period
Cholesterol Lesion size Composition Reference
phospholipid-
rich
particles"
Less cellular
apoA-IV" Collagen"
IFN-g
2/2/LDLr
2/2 (MþF) D12108
research
diets
40% lipid/ 1.25%
chol
5–6wþ 8w $ 75%# lipid area T-cells$ 74
62%# lesion area Macrophages#
En face 46%# MHCII
þcells #
Collagen#
5–6wþ 20 w $ 43%# lipid area $
Lesion area $ MHCII
þcells #
en face 70%#
Anti-
IFN-g
ApoE
2/2þsIFN-gR plasmid Western-type
diet
20% fat/ 0.15% chol 8 w þ 4w $ en face plaque
area 60%#
IFN-g, Il-1b, MCP-1,
VCAM-1#
78
Western-type
diet
20% fat/ 0.15% chol 8 w þ 8w $ Attenuate lesion
progression
50%,
stabilization
Inﬂammatory cyto/
chemokines#
96
MMP-9/13#
Collagen I"
8wþ 12 w $ Attenuate lesion
progression
40%
pSTAT1/STAT1#
CD40/CD40L#
MIF ApoE
2/2þa-MIF mAb Chow ? þ 14 w $ Lesion area %#
n.s.
4x#Macrophages 71
Inﬂammatory mediators#
ApoE
2/2þa-MIFAb Atherogenic
diet
? þ 16 w Aortic root
surface#
T-cells# 2
Macrophages#
Mif2/2/LDLr2/2 Chow 0 w þ 30 w Monocyte adhesion# 2
Macrophages#
Mif2/2/LDLr2/2 (M) Atherogenic
diet
6wþ 12/26 w LDL# 26 w: En face
lipid
deposition
4.5x#
Ki67þcells# 70
HDL$ Longitudinal
intima 7x#
SMCs#n.s.
TG# Collagen#n.s.
ApoE
2/2þMIF mAbþcarotid
transluminal wire injury
Atherogenic
diet
21% fat 8 w þ 3w $ Neointima/
media
volumes$
Macrophages 2x# 72
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8SMC2x"
LDLr
2/2þa-MIF mAbþcarotid
injury
HF 20.1% fat/1.25%
chol
Weaningþ12 w $ Neointimal
thickening
54%#
Proliferation 56%# 73
CD45þ cells 27%#
Apoptosis"
M-CSF Op0/op1/op2/ ApoE
2/2
(MþF)
Chow 0 w þ 16 w Op1 " Op1 # 85
Op0 "" Op0 ##
VLDL
Op0/op1/op2/ ApoE
2/2
(MþF)
Chow 12 w þ 12 w Op0: 2.5x" Op0: M: no
lesions
86
HDL$ F: 98%#
Op1:M: 60%#
F:85%#
Op0/op1/op2/C57Bl6 Atherogenic
diet
15% fat/ 1.25% chol/
0.5% cholic acid
24 w þ 15 w Op0: 2x" Op0: 84%# 86
Op1:3x" Op1: 46%#
Op0/op1/op2/ ApoE
2/2
(MþF)
Western-type
diet
42% fat/ 0.15% chol 3 w þ 9 w Op0: 1.5x" Op0: 4x# Monocytes 3x# 4
Chow 4.5% fat/0.02% chol 4 w þ 12 w Op0:# Macrophages#
Op/þ, op/op/ LDLr
2/2 (MþF) Atherogenic
diet
15% fat/ 1.25% chol/
0.5% cholic acid
12 w þ 16 w Op/op 25%" Op/op 99.7%# 5
Op/þ16%" Op/þ99.4%#
ApoE
2/2 (F)þmurine c-fms
mAb
HF 20% fat/ 0.3% chol 6 w þ 6 w dietþ6wA b $ 70%# 87
6wþ 12 w diet þ 6wA b $$ Macrophages$
SMC$
GM-CSF GM-CSF
2/2, GM-CSF
þ/2/
LDLr
2/2 (MþF)
Western-type
diet
TD88137, teklad 10 w þ 12/13 w $ 2/2: 20%# Macrophages$ 88
þ/2: # SMC$
Collagen$
Elastin#
CD11cþ cells 63%#
CD4þ Thcells 50%#
IL-6/MCP-1$
ApoE
2/2 (M)þGM-CSF (10 mg/
kg
21d
21; 5 d per w)
Paigen diet 30 kcal % fat/ 1.25%
chol/0.5% cholate
8wþ 8w $ 2x"$ 89
G-CSF GM-CSF
2/2/ApoE
2/2 (M) HF 20% fat/0.125% chol 8 w þ 12 w $ 30%" Macrophages 2x" 90
SMC$
Collagen 15%#
PPARg 50%#
ABCA1, SR-A, CD36#
ApoE
2/2 (M)þG-CSF (10 mg/
kg
21d
21; 5 d per w)
Paigen diet 30 kcal % fat/ 1.25%
chol/0.5% cholate
8wþ 8w $ 44%"$ 89
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9To re-examine the hypothesis that IL-6 and the acute-
phase-response play an important role in atherogenesis,
Song and Schindler
34 crossbred IL-6
2/2 mice with LDLR
2/2
mice because loss of ApoE protein in ApoE
2/2 mice has
been associated with decreased immune and inﬂammatory
responses.
11,35 Although there was a trend for modestly
smaller lesions in IL-6
2/2/LDLR
2/2 throughout the course of
the study of 16 weeks on chow, Western-type, and Paigen
diets, these differences never achieved statistical signiﬁ-
cance. This despite a signiﬁcant defect in the expression of
acute-phase-response genes in IL-6
2/2/LDLR
2/2 Paigen diet
fed mice. Similar to the development and structure of
atheromata, no signiﬁcant differences in lipid/lipoprotein
were noted, indicating that IL-6 does not contribute signiﬁ-
cantly either to the regulation of lipid metabolism on chow,
Western-type, or Paigen diet fed LDLR
2/2 mice.
In all, reported studies support both a positive and nega-
tive role for IL-6 in the development of atherosclerosis,
while some groups failed to identify a substantial role for
IL-6 at all in either the development or structure of athero-
mata. Part of the explanation for the different ﬁndings may
lie in the experimental set-up (mouse model, male vs.
female, diet, age of the animals, duration of the exper-
iment; Table 1). Also, IL-6 may have a biphasic effect on
the atherosclerotic process as a reﬂection of its pro-
inﬂammatory or anti-inﬂammatory nature activities.
36–38
Furthermore, redundancy may play an important role. IL-6
belongs to a family of cytokines, which include IL-11,
leukaemia inhibitory factor, oncostatin M, and ciliary-
neurotropic factor, which are expressed in the arterial
wall. Since these IL-6-type cytokines all use the same recep-
tor gp130 subunit for signal transduction, they may induce
similar (patho)physiological responses as IL-6 and overcome
IL-6 deﬁciency (‘redundancy’).
8. Interleukin-10
IL-10 is a pleiotropic cytokine produced by a variety of
immune cells (e.g. TH2 cells, macrophages and CD8
þ cells)
that can inhibit a broad array of immune and inﬂammatory
responses.
39 Because of its anti-inﬂammatory properties,
IL-10 is thought to be atheroprotective and have anti-
atherogenic potential.
Indeed, atherosclerosis is reduced in IL-10-transgenic
C57/BL6-mice fed a cholate-containing HF-diet,
40 whereas
their IL-10-deﬁcient counterparts exhibited increased early
atherosclerotic lesion formation (Table 1).
40,41 Caligiuri
et al.
95 also showed a protective effect of IL-10 by using
ApoE
2/2/IL-10
2/2 mice: IL-10-deﬁciency increased athero-
sclerosis, LDL, thrombosis, and plaque vulnerability. In line
with this, intramuscular gene transfer of IL-10 cDNA
reduced atherosclerosis in ApoE
2/2 mice.
42 Inhibition of
atherogenesis was also found by delivery of adeno-
associated virus vector-mediated IL-10 (AAV/IL-10) gene
transfer into the tibial muscle of ApoE
2/2 mice
43 or by
AAV/IL-10 tail vein injection in LDLR
2/2 mice.
39 Because
IL-10 is produced by BM cells, two groups
44,45 examined
the direct role of leukocyte-derived IL-10 on the inﬂamma-
tory process and development of advanced atherosclerotic
lesions in irradiated LDLR
2/2 mice transplanted with BM
cells from IL-10 transgenic,
44 wild-type
45 or IL-10
2/2
mice. After feeding a HF/cholate-free diet, IL-10 deﬁciency
signiﬁcantly enhanced development of advanced
atherosclerotic lesions, reiterating that leukocytes are a
major source of IL-10, active in protection against excessive
growth of advanced lesions.
9. Interleukin-12
IL-12 is a heterodimeric (p70) cytokine consisting of a 35 kDa
light chain (p35) and a 40 kDa heavy-chain (p40). IL-12 is
produced by various inﬂammatory cell types present in the
atherosclerotic vasculature, among which macrophages.
Because of its early production in response to stimuli and
its ability to enhance TH1-cell differentiation, IL-12 forms
a bridge between innate and adaptive immunity.
46
IL-12 p40
2/2 /ApoE
2/2 mice show markedly less athero-
sclerosis in the aortic root at 30 weeks of age than ApoE
2/2
controls (Table 1).
23 In addition, daily administration of
IL-12 protein promotes atherosclerosis in young ApoE
2/2
mice compared with control-treated mice.
47 Hauer et al.
48
reported that functional blockade of endogenous IL-12 by
vaccination resulted in a signiﬁcant 69% reduction of athero-
genesis induced in carotid arteries by bilateral perivascular
collar placement using LDLr
2/2 mice; vaccination against
IL-12 also improved parameters for plaque stability.
These studies, in which the pro-atherosclerotic role of
IL-12 is described, indicate that IL-12 may be a suitable
target in the treatment of atherosclerosis.
10. Interleukin-18
IL-18 and IL-1b are members of the same structural family
(IL-1 family). Animal experiments support the concept that
IL-18 participates in the pathogenesis of atherosclerosis
(Table 1). When injected for 30 days with IL-18, ApoE
2/2
mice exhibit a doubling of the lesion size through release
of the pro-inﬂammatory cytokine IFN-g, and without a
change in serum cholesterol.
49
Elhage et al.
50 found reduced atherosclerosis in
IL-18-deﬁcient ApoE
2/2 mice, despite an increase in serum
cholesterol. Overexpression of the IL-18-binding protein, a
naturally occurring, speciﬁc inhibitor of IL-18, prevents the
spontaneous development of atherosclerosis in ApoE
2/2
mice,
51 thus conﬁrming the pro-atherogenic character of
IL-18. Part of the pro-atherogenic effect of IL-18 may be
indirect since IL-18, in particular in combination with IL-12,
is a potent inducer of the production of IFN-g, which has
aggravating effects on atherosclerosis (see below).
52,53
11. Interleukin-20
IL-20 belongs to the IL-10 family and is a proinﬂammatory
cytokine, preferentially expressed in monocytes. Systemic
delivery of IL-20 by intramuscular electroporation of IL-20
expression vector resulted in increased atherosclerotic
lesion areas in ApoE
2/2 mice, suggesting that IL-20 acts as
a pro-atherogenic cytokine.
54
12. Tumour necrosis factor-a
TNF-a is a pleiotropic cytokine that exerts potent
pro-inﬂammatory effects in atherosclerosis and other meta-
bolic and inﬂammatory disorders such as obesity and insulin
resistance which are also risk factors for cardiovascular
diseases. TNF-a is primarily produced by monocytes and
R. Kleemann et al. 370macrophages. The involvement of TNF-a in the pathogenesis
of atherosclerosis is supported by its presence in human
atherosclerotic plaques. Furthermore, circulating TNF-a
levels are associated with increased risk of recurrent myo-
cardial infarction, atherosclerotic thickening of carotid
intima-media, disturbances in triglyceride and glucose
homeostasis, and with age-related atherosclerosis.
Lymphotoxin-a (LTa) is another member of the TNF ligand
family and is synthesized predominantly by activated T- and
B-lymphocytes. Like TNF-a,L T a is expressed in athero-
sclerotic plaques. TNF-a and LTa elicit responses through
two receptors termed p55 (TNFR1) and p75 (TNFR2), of
which p55 activates the majority of biological responses.
The role of TNF-a (and LTa) in atherosclerosis is not fully
clear at present because results in animal models are con-
troversial (Table 1).
In female C57/BL6 wild type mice lacking p55 (p55
2/2
mice), Schreyer et al. found an unexpected 2.3-fold
increase in atherosclerosis when feeding the mice an athero-
genic diet.
55 In a subsequent study, the same group found
that loss of p75 did not alter lesion development, and loss
of both p55 and p75 resulted in lesion areas comparable
with those for p55
2/2 mice.
56 No signiﬁcant changes in
plasma lipid levels were observed between genotypes. By
contrast, in older p55
2/2 mice on an ApoE
2/2 background
no effect on lesion progression or composition of very
advanced plaques was observed.
57 Using an arterial grafting
model (i.e. transplantation of lesion-free wild-type- or
p55
2/2-donor carotid grafts in ApoE
2/2 recipient mice)
Zhang et al. demonstrated that expression of p55 in just
the arterial wall (SMC and EC) contributed substantially to
both early-stage and late-stage atherosclerosis by enhancing
adhesion molecule and chemokine expression as well as SMC
proliferation.
58 The authors also analyzed atherosclerosis
in 60-week-old p55
2/2/ApoE
2/2 and ApoE
2/2 mice and
showed that p55-deﬁciency results in 12% less thoracic
atherosclerosis at comparable cholesterol levels.
Campbell et al. also reported diminished atherosclerotic
lesion development in male p55
2/2 mice fed a HF/
HC-diet.
59 In addition, these investigators showed that sig-
nalling through the p55 receptor may also play a role in
the atherogenic effects of C. pneumoniae in hyperlipidae-
mic mice. Whereas C. pneumoniae-infected male
C57/BL6J2mice on HF/HC-diet showed a 2.5- to 3.3-fold
enlarged lesion size in the aortic sinus in comparison to
uninfected mice, no acceleration of atherosclerotic lesion
development was observed in infected p55
2/2 mice com-
pared to uninfected controls. No differences in total
plasma cholesterol values were observed between infected
and sham-inoculated animals.
Elhage et al.
14 used repeated subcutaneous injections of
a speciﬁc TNF/LT inhibitor (TNF-binding-protein; TNFbp)
consisting of two molecules of the extracellular domain of
p55 linked to a polyethylene glycol molecule, which binds
with equal afﬁnity to both TNF-a and LTa. This treatment
of ApoE
2/2 mice with TNFbp did not affect total plasma
cholesterol, but there was a tendency to a decrease in
fatty streak area in females, not in males. In this study,
however, the duration of TNFbp treatment was relatively
short (1 month) and the cytokine antagonist was delivered
subcutaneously.
Involvement of TNF-a and/or LTa in the progression
of atherosclerosis was further substantiated by Branen
et al.
60 Mice deﬁcient in both ApoE and TNF-a exhibited a
50% reduction in lesion size after 10 weeks of Western-style
diet feeding. In ApoE
2/2 mice treated with recombinant
soluble p55-receptor-releasing pellets, the lesion size was
75% reduced (after 25 weeks).
Similarly, Ohta et al.
61 reported that disruption of the
TNF-a gene diminishes atherosclerosis development in
ApoE
2/2 mice without affecting serum cholesterol. Kober
et al.
62 conﬁrmed this observation and further demon-
strated by MRI that lesion progression and atherosclerotic
wall-thickening is reduced in TNF
2/2/ApoE
2/2mice.
Chew et al.
63 administered thalidomide, an inhibitor of
TNF-a production, to female ApoE
2/2 mice fed a HF
Western-type diet without cholate and reported a signiﬁ-
cantly smaller lesion size by thalidomide as compared to
placebo-treatment.
Boesten et al.,
64 using TNF-a-deﬁcient ApoE*3Leiden mice
fed a cholesterol-rich diet, found that the absence of TNF-a
did not affect atherosclerotic lesion area, but inhibited
lesion progression towards an advanced phenotype.
Canault et al.
65 investigated the effect of a transmem-
brane form of TNF-a on atherosclerosis in male mice. They
compared the development of early atherosclerotic lesions
in (i) TNF
2/2 mice that express only a non-cleavable trans-
membrane form of TNF (tmTNF mice), (ii) wild-type C57/
BL6 (WT) mice, and (iii) TNF
2/2 mice, all fed an atherogenic
diet for 20 weeks. Lipid deposition was most prominent in
WT, tended to be lower in tmTNF mice, and rare in
TNF
2/2 mice. Macrophage accumulation was ﬁve-fold
lower in tmTNF than in WT mice.
In WT mice, the plasma lipid proﬁle was more atherogenic
than that of TNF
2/2 mice, but not signiﬁcantly different
from that of tmTNF mice. These results indicate that in con-
trast to TNF
2/2 mice, mice expressing exclusively tmTNF
are not completely protected from early atherosclerotic
lesion formation, although their lesions have a less inﬂam-
matory state than those of WT mice, which underlines the
stronger pro-inﬂammatory potential of soluble TNF.
In contrast to Canault et al., and seemingly at variance
with their ﬁndings with p55
2/2 mice,
55 loss of TNF-a did
not alter lesion development in female C57/BL6 mice in
experiments described by Schreyer et al., while LTa
deﬁciency resulted in a marked 62% reduction in lesion
size.
56 The disparity in results obtained by Schreyer et al.
between ligand- and receptor-deﬁcient mice suggests
there are undeﬁned members of the TNF ligand and receptor
signalling pathway involved with regulating atherogenesis.
13. Macrophage migration inhibitory factor
MIF is a pleiotropic cytokine with hormone-like and
enzymatic properties.
66 Unique among cytokines is MIF’s
uptake into target cells where it controls cell cycle and
inﬂammation.
67,68 MIF is predominantly released from
macrophages, T-lymphocytes, and SMC, and was shown to
be increasingly expressed during atherogenesis,
69 with
oxLDL being a major inducer.
Genetic MIF-deletion in LDLR
2/2 mice retarded the
atherosclerotic process and resulted in reduced intimal
thickening, SMC proliferation, lipid deposition, and
protease expression (both cathepsins and matrix metallo-
proteinases)
70 (Table 1). After 26 weeks on an atherogenic
diet, 20% of the MIF
2/2/LDLR
2/2 mice had developed
Cytokines and atherosclerosis: studies in mice 371only early, fatty-streak-like lesions, whereas .80% of the
LDLR
2/2 mice displayed advanced lesions containing calciﬁ-
cation and lipid cores. Antibody blockage of MIF signiﬁcantly
reduced (by 75%) intimal macrophage inﬁltration in
ApoE
2/2 mice undergoing spontaneous atherosclerosis and
diminished the aortic plaque area.
71 Schober et al.
72
showed that MIF antibody treatment also diminishes neointi-
mal macrophage/foam cell content after endothelial denu-
dation. In the same study, SMC and collagen content were
increased, reﬂecting a shift in plaque composition towards
a stable phenotype. Decreased neointimal thickening and
cellular proliferation was also shown in LDLR
2/2 mice on a
C57/BL6J background undergoing carotid injury.
73 Seven
days after surgery, anti-MIF treatment reduced the number
of inﬂammatory CD45-positive cells invading the intima by
27%. In accordance with this anti-inﬂammatory effect
achieved with MIF antibody treatment, Burger-Kentischer
et al.
71 reported that immunoneutralization of MIF reduces
parameters of aortic (CD40L, ICAM, and MMP-2) and systemic
inﬂammation (SAA, ﬁbrinogen, and IL-6).
A recent study demonstrates that blockage of MIF in
ApoE
2/2 mice with established advanced atherosclerotic
lesions leads to plaque regression and reduces monocyte
and T-cell content in atherosclerotic lesions.
2 Using
ApoE
2/2 mice, MIF
2/2/LDLR
2/2 mice, and anti-MIF anti-
bodies, the authors showed that MIF functions as a non-
cognate CXCR ligand and plays a prominent role in the
recruitment of macrophages, T-cells, and neutrophils. The
proatherogenic effects of MIF may thus mainly be explained
by its cell arrest and chemoattractant functions.
14. Interferon-g
The pleiotropic cytokine IFN-g is a pro-inﬂammatory
mediator that is expressed at high levels in atherosclerotic
lesions by various cells, including monocytes/macrophages,
TH1 cells, and natural killer T-cells (NKT).
6 Activated NKT
can produce signiﬁcant amounts of IFN-g and are
pro-atherogenic in mice (Hansson and Libby
1 and references
cited therein). IFN-g has been implicated in the athero-
sclerotic process via direct effects
53,74–76 and indirectly via
IL-12 and IL-18
23,50,77 (Table 1).
Daily injection of recombinant IFN-g in ApoE
2/2 mice sig-
niﬁcantly increased lesion size 2-fold, despite a 15%
decrease in serum cholesterol levels.
76 IFN-g administration
also signiﬁcantly increased the number of T-cells within
lesions. The pro-inﬂammatory role of IFN-g was further
underscored in studies using IFN-g
2/2/ApoE
2/2 mice.
75
Deﬁciency of endogenous IFN-g decreased atherosclerosis
development in male ApoE
2/2 mice fed a normal or
HF-diet. This decrease was associated with a decreased
abundance and activation of T-cells, without changes in
serum cholesterol. Deﬁciency of IFN-g has also been shown
to substantially decrease extent and inﬂuence phenotype
of atherosclerosis in male and female LDLR
2/2 mice,
without concomitant changes in lipoprotein proﬁles.
74
In line with this, female IFN-gR
2/2/ApoE
2/2 mice fed a
Western-type diet showed a substantial reduction in lesion
size, a 60% reduction in lesion lipid accumulation, a
decrease in lesion cellularity, and a marked increase in
lesion collagen content. Notably, the IFNgR
2/2/ApoE
2/2
mice exhibited a signiﬁcant increase in potentially athero-
protective phospholipid/apoA-IV rich particles.
53 Koga
et al.
78 investigated blocking of IFN-g function by overex-
pressing a soluble mutant of IFN-g receptor (sIFNgR) in
ApoE
2/2 mice and found a reduced luminal plaque area.
There is also indirect evidence for a role of IFN-g in
atherogenesis. One of the primary factors regulating IFN-g
secretion is IL-18. Whitman et al.
77 demonstrated that the
absence of IFN-g in IFN-g
2/2/ApoE
2/2 mice ablated the
effects of recombinant IL-18 administration on athero-
sclerosis. Elhage et al.
50 reported that IL-18
2/2/ApoE
2/2
mice exhibited a substantial, 35% reduction in lesion size
when compared with IL-18-competent littermates, while
the compound knockout mice displayed reduced I-A
b gene
expression, implying reduced local IFN-g stimulation.
IL-18 functions synergistically with other co-stimulators,
particularly IL-12, to induce pronounced secretion of IFN-g
by macrophages and T-cells. Compared to ApoE
2/2 mice,
IL-12
2/2/ApoE
2/2 mice displayed a 52% reduction in
plaque area in the aortic root at 30 weeks of age,
23 similar
to that reported in IFN-gR
2/2/ApoE
2/2 mice (which also
have impaired TH1 responses).
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15. Colony stimulating factors
CSFs are key cytokines involved in the survival, prolifer-
ation, and differentiation of myeloid progenitor cells as
well as the functional activation of mature myeloid cells.
Four CSFs have been cloned and characterized: multi-CSF/
IL-3 (produced by TH1a n dT H2-cells), granulocyte
macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF¼CSF-1),
and granulocyte-CSF (G-CSF).
79 The CSFs have a signiﬁcant
overlap in their biological actions. G-CSF and M-CSF are
essentially lineage-restricted in their actions on neutrophil
and macrophage precursors while GM-CSF and IL-3 also can
stimulate other cell types. A comprehensive body of evi-
dence now exists that CSFs have actions in cardiovascular
diseases, among which atherosclerosis
80,81 (Table 1).
M-CSF has been implicated in a variety of inﬂammatory
disorders, including atherosclerosis (see references
5,80
and references therein). Atherogenic oxidized LDLs
induce aortic EC and SMC expression of M-CSF, partly
through activation of NF-kB.
5,82–84 The localized
expression of M-CSF in the vessel wall may be critical in
promoting the survival of lipid-laden foam cells observed
in early and advanced stages of atherosclerosis. M-CSF
selectively regulates the growth and survival of mono-
nuclear phagocytes by binding to a speciﬁc cell surface
receptor, c-fms. In addition, M-CSF functions as a chemo-
tactic factor for monocytes and regulates the effector
functions of mature monocytes and macrophages, i.e. it
modulates inﬂammatory responses by stimulating the pro-
duction of other cytokines (e.g. IL-6, IL-8, IL-12, IL-18,
and TNF-a) and growth factors.
Osteopetrotic (op/op) mice that lack M-CSF due to a point
mutation in the M-CSF gene have proven to be useful in
examining the role of M-CSF in atherogenesis. Smith
et al.
85 found that op/ApoE
2/2 mice fed a low-fat diet
had signiﬁcantly smaller proximal aortic lesions than their
ApoE
2/2 littermates, despite an almost 3-fold increase in
plasma cholesterol. Qiao et al.
86 reported experiments in
which atherogenesis was induced either by feeding op/op
mice a HF/HC-diet or by crossbreeding these mice
with ApoE
2/2 mice to generate M-CSF
2/2/ApoE
2/2 mice.
In both cases, M-CSF deﬁciency signiﬁcantly reduced
R. Kleemann et al. 372atherogenesis. The effect of the M-CSF deﬁciency appears
not to be mediated by changes in lipoproteins, because
deﬁcient mice exhibited higher levels of atherogenic lipo-
protein particles. De Villiers et al.
4 also reported that
mice deﬁcient in M-CSF (op) and ApoE display elevated
cholesterol levels but are protected from atherosclerosis,
thereby illustrating the importance of both M-CSF and
M-CSF-dependent monocytes/macrophages in maintaining
cholesterol homeostasis and in atherogenesis.
Using LDLR
2/2 mice, Rajavashisth et al.
5 showed that
atheroma development depends on M-CSF concentration,
as not only did homozygous op/op mice have dramatically
reduced lesions (0.3% of control lesion size) but heterozy-
gous (op/þ) mice had lesions ,1% of controls. Plasma M-CSF
levels in heterozygous (op/þ) mice were about half of those
in controls (þ/þ). The ﬁnding that a 2-fold reduction in
M-CSF expression reduced lesion size 100-fold suggests
the requirement for a threshold level of M-CSF. The effects
of M-CSF on atherosclerosis in LDLR
2/2 mice did not
appear to be mediated by changes in plasma lipoproteins
or alterations in the number of circulating monocytes,
since both op/op and op/þ mice exhibited higher levels of
atherogenic lipoprotein particles,
86 and (op/þ) mice
showed a near normal number of circulating monocytes.
Taken together, these results suggest that the effects
of M-CSF on atherogenesis are not mediated by systemic
M-CSF or by changes in monocyte numbers, but that local
M-CSF plays an essential role in the arterial wall itself.
Importantly, M-CSF is critical for promoting the early
stages of atherosclerosis since administration of a mono-
clonal antibody against c-fms, the receptor of M-CSF,
protects from early atherogenesis but does not attenuate
progression of already developed lesions in ApoE
2/2
mice.
87 SMC can also express c-fms and it has
been suggested that activation of these cells by M-CSF
may promote development of smooth-muscle-derived
foam cells.
Similar to M-CSF, GM-CSF is induced in EC by oxidized
lipids
84 and abundantly present in atherosclerotic
lesions.
88 Its function overlaps with that of M-CSF. GM-CSF
appears a major regulator speciﬁcally of dendritic cell
differentiation and aortic lesional dendritic cell accumu-
lation. So far, reported ﬁndings on the effect of GM-CSF on
atherosclerosis are inconsistent. Hyperlipidaemic LDLR
2/2
mice with a GM-CSF deﬁciency exhibited 20–50% decrease
in aortic lesion size, depending on the location of the lesions
and the sex of the animals.
88 Similarly, treatment of male
ApoE
2/2 mice (fed a cholate-containing diet) with murine
GM-CSF (10 mgk g
21 day
21 subcutaneously) increased the
atherosclerotic lesion area by 2-fold.
89 In contrast to both
studies, genetic deletion of GM-CSF in ApoE
2/2 mice
increased atherosclerotic lesion size, without affecting
plasma cholesterol.
90 In the latter study, animals were not
fed cholate. Furthermore, the collagen content in the
lesions was reduced, suggesting the formation of unstable
plaques.
While both M-CSF and, to some lesser extent, GM-CSF
have been extensively studied in atherosclerosis and other
inﬂammatory disorders, G-CSF and multi-CSF/IL-3 have
received hardly any attention hitherto. Haghighat et al.
89
showed that subcutaneous administration of G-CSF
(10 mgk g
21 day
21) in ApoE
2/2 mice over an 8-week period
resulted in a 44% increase in atherosclerotic lesion extent,
without alterations in plasma lipids or vascular and systemic
inﬂammation markers. No studies on the role of IL-3 in
atherosclerosis have been described yet.
In summary, of the four CSFs characterized, only endogen-
ous M-CSF has been consistently found proatherogenic,
most probably by inﬂuencing the lesional macrophage phe-
notype. GM-CSF has been attributed both pro-atherogenic
and anti-atherogenic properties, while the role of G-CSF
and multi-CSF/IL-3 in atherosclerosis needs further
research.
16. Summary and conclusions
Inﬂammatory processes are involved at all stages of the
atherosclerotic process, from lesion initiation to plaque
rupture. Potentially, cytokines play an important role in
the pathogenesis of atherosclerosis and thus could act as
important targets for anti-atherosclerotic strategies, on
top of those directed at cholesterol-lowering.
Here, we have summarized all currently available infor-
mation from mice studies on the contribution of interleu-
kins, macrophage-related cytokines, and CSFs to lesion
evolution. Table 2 provides a global overview on the overall
effects of these cytokines on plasma cholesterol and
atherosclerosis in C57/BL6, ApoE
2/2, and LDLr
2/2 mice.
An important outcome of this survey is that several cyto-
kines show explicit and consistent pro-atherogenic effects,
generally independent of the experimental approach and
conditions chosen: IL-1, IL-12, IL-18, TNF-a, MIF, IFN-g,
and M-CSF all display pro-atherogenic characteristics while
IL-10 clearly has anti-atherogenic properties (Figure 2B).
Some cytokines have a dual character and show variable
effects: IL-4, IL-6, and GM-CSF can have pro- or anti-
atherogenic properties, depending on the mouse model
and gender used, disease stage analysed, and dietary con-
ditions applied. Only a few studies have tested IL-2, IL-20,
G-CSF (all showing pro-atherogenic characteristics so far),
or IL-5 (anti-atherogenic to this point), and additional
experimental evidence is required before deﬁnitive con-
clusions can be drawn. Another key result of this review is
that several of the pro-atherogenic cytokines (IL-1, IL-18,
TNF-a, IFN-g, MIF, and M-CSF) affect plasma cholesterol
levels, underscoring the notion that inﬂammation and lipid
metabolism are interlinked processes.
2,91–93
Overall, our survey provides support for the notion that
modulating the activity of selected cytokines (either sys-
temically or locally) can block or retard the development
of atherosclerotic lesions and thus positively inﬂuence
disease outcome. The signiﬁcant impact of selected cyto-
kines on atherogenesis could be of signiﬁcance for early
detection and prevention of the disease, and also provides
new opportunities for anti-atherosclerotic treatment regi-
mens, alone or in combination with established hypolipi-
daemic or hypotensive strategies. Importantly, in the
studies described in this review, the activity of the cyto-
kine of interest was modulated by techniques such as
genetic deletion, overexpression, immunoneutralization,
or in vivo administration of the cytokine or its receptor
or inhibitor, techniques not easily applicable to humans.
The chronic nature of the atherosclerotic disease process
and the generally pleiotropic effects of cytokines will
demand high speciﬁcity of action and/or effective
Cytokines and atherosclerosis: studies in mice 373targeting to prevent the emergence of adverse side effects
with clinical applications.
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